Immunotherapy Focus Nurix Therapeutics is developing novel, small molecule immuno-oncology agents for cancer treatment, presenting a prime opportunity to collaborate with healthcare institutions and oncology clinics seeking innovative immunotherapy solutions.
Growing Pipeline Programs With the presentation of preclinical data from pipeline programs NX-5948 and GS-6791, Nurix showcases its commitment to expanding its drug portfolio, indicating potential partnerships for co-development or licensing agreements.
Strategic Leadership Additions Recent appointments of Anil Kapur to the board of directors and Julia P. Gregory as the board chair demonstrate Nurix's emphasis on bolstering its leadership team. This presents an opportunity to engage with key decision-makers and explore synergistic collaborations.
Prominent Market Attention Nurix's focus on developing protein modulation drugs for cancer and inflammatory diseases has garnered significant attention from analysts and investors. This visibility offers a platform for engaging with potential investors or strategic partners interested in biopharmaceutical advancements.
Financial Stability and Growth With revenue in the range of $50-100M and recent funding of $175M, Nurix demonstrates financial stability and growth potential. This positions the company as a reliable partner for investors, biotech firms, or pharma companies looking to invest in established players in the biotechnology research sector.
$10M
$50M$100M
$50M$100M
$10M$50M
$10M$50M
$10M$50MNurix Therapeutics uses 8 technology products and services including GoTo Meeting, jQuery CDN, Google Cloud, and more. Explore Nurix Therapeutics's tech stack below.
| Nurix Therapeutics Email Formats | Percentage |
| FLast@nurixtx.com | 77% |
| Last@nurixtx.com | 19% |
| First.Last@nurixtx.com | 4% |
| FLast@nurix-inc.com | 88% |
| Last@nurix-inc.com | 8% |
| First@nurix-inc.com | 1% |
| FMiddleLast@nurix-inc.com | 1% |
| F.Last@nurix-inc.com | 1% |
| LastF@nurix-inc.com | 1% |
Biotechnology ResearchCalifornia, United States201-500 Employees
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
Company Overview
Funding & FinancialsNurix Therapeutics has raised a total of $175M of funding over 8 rounds. Their latest funding round was raised on Apr 11, 2024 in the amount of $175M.
Nurix Therapeutics's revenue is in the range of $50M$100M
Funding & FinancialsNurix Therapeutics has raised a total of $175M of funding over 8 rounds. Their latest funding round was raised on Apr 11, 2024 in the amount of $175M.
Nurix Therapeutics's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com